FTC Wants To Block Steris/Synergy Merger
This article was originally published in The Gray Sheet
Executive Summary
The companies plan to contest the Federal Trade Commission's action, although they say they have yet to see FTC's formal complaint. The deal, valued at $1.9 billion, would allow U.S.-based Steris to reduce its corporate tax rate by redomiciling to Synergy's home in the U.K., creating a $2.6 billion entity.
You may also be interested in...
Medtech 2014: M&A, IPOs Bounce Back As Industry Glimpses Future Business Models
Healthy market growth, the biggest ever M&A deal, a record number of billion-dollar takeovers, and the IPO market in impressive bounce-back…2014 was a year of superlatives for the global medtech industry. But with more expected of manufacturers while health care spending remains in the doldrums and demand for care rises, the long-term medtech winners will be those who can forecast how and where to make an impact on both costs and patient outcomes.
Steris Buys Synergy For $1.9 Billion To Create Sterilization Giant
The deal for UK-based Synergy follows the trend of U.S. companies moving their headquarters to take advantage of more favorable tax rates, but Steris says the acquisition also makes sense because the companies’ geographies and product ranges are complementary.
Outlook 2023: Market Experts On Importance Of Value, Mental Health In A ‘World On Fire’
Competitive value propositions are a must in 2023 to win guarded consumers’ business. Companies that effectively address mental health and wellbeing needs and appeal to consumers through sustainability initiatives could have an edge in the recessionary environment, experts suggest. Meanwhile, there are concerns about small cosmetics companies and the availability of resources to help them comply with "modernized" federal regulations.